Journal
CELLULAR & MOLECULAR IMMUNOLOGY
Volume -, Issue -, Pages -Publisher
CHIN SOCIETY IMMUNOLOGY
DOI: 10.1038/s41423-023-01093-y
Keywords
Antitumor immunity; CD8(+) T cell; T-cell-based immunotherapy; TRAF6; CTLA-4
Categories
Ask authors/readers for more resources
This study reveals the regulatory mechanism of CTLA-4 stability mediated by TNF receptor-associated factor 6 (TRAF6) and suggests its functional significance in CD8(+) T-cell-mediated antitumor immunity. Additionally, the OX40-TRAF6 axis is found to be responsible for CTLA-4 degradation, thus controlling antitumor immunity in both tumor-bearing mice and patients with cancer. These findings highlight the potential of targeting the OX40-TRAF6 axis to improve T-cell-based immunotherapies.
Immune checkpoint blockade (ICB), including anti-cytotoxic T-lymphocyte associated protein 4 (CTLA-4), benefits only a limited number of patients with cancer. Understanding the in-depth regulatory mechanism of CTLA-4 protein stability and its functional significance may help identify ICB resistance mechanisms and assist in the development of novel immunotherapeutic modalities to improve ICB efficacy. Here, we identified that TNF receptor-associated factor 6 (TRAF6) mediates Lys63-linked ubiquitination and subsequent lysosomal degradation of CTLA-4. Moreover, by using TRAF6-deficient mice and retroviral overexpression experiments, we demonstrated that TRAF6 promotes CTLA-4 degradation in a T-cell-intrinsic manner, which is dependent on the RING domain of TRAF6. This intrinsic regulatory mechanism contributes to CD8(+) T-cell-mediated antitumor immunity in vivo. Additionally, by using an OX40 agonist, we demonstrated that the OX40-TRAF6 axis is responsible for CTLA-4 degradation, thereby controlling antitumor immunity in both tumor-bearing mice and patients with cancer. Overall, our findings demonstrate that the OX40-TRAF6 axis promotes CTLA-4 degradation and is a potential therapeutic target for the improvement of T-cell-based immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available